SNSE Key Statistics, Chart & Performance
The current stock price of SNSE is 11.615 USD. In the past month the price increased by 35.53%. In the past year, price increased by 13.32%.
SNSE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B |
Related stock screener links
About SNSE
Company Profile
Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company is headquartered in Rockville, Maryland and currently employs 14 full-time employees. The company went IPO on 2021-02-04. Through its Tumor Microenvironment Activated biologics (TMAb) platform, the Company develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment to unleash T cells against tumors. Its lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation checkpoint selectively within the low pH tumor microenvironment. The company is also developing SNS-102, a conditionally active monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4); SNS-103, a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), CD39; and SNS-201, a conditionally active VISTAxCD28 bispecific antibody.
Company Info
SENSEI BIOTHERAPEUTICS INC
1405 Research Blvd, Suite 125
Rockville MARYLAND 20850 US
CEO: John Celebi
Employees: 15
Phone: 12402438000
SENSEI BIOTHERAPEUTICS INC / SNSE FAQ
Can you describe the business of SENSEI BIOTHERAPEUTICS INC?
Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company is headquartered in Rockville, Maryland and currently employs 14 full-time employees. The company went IPO on 2021-02-04. Through its Tumor Microenvironment Activated biologics (TMAb) platform, the Company develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment to unleash T cells against tumors. Its lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation checkpoint selectively within the low pH tumor microenvironment. The company is also developing SNS-102, a conditionally active monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4); SNS-103, a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), CD39; and SNS-201, a conditionally active VISTAxCD28 bispecific antibody.
What is the stock price of SENSEI BIOTHERAPEUTICS INC today?
The current stock price of SNSE is 11.615 USD. The price increased by 5.02% in the last trading session.
Does SENSEI BIOTHERAPEUTICS INC pay dividends?
SNSE does not pay a dividend.
What is the ChartMill rating of SENSEI BIOTHERAPEUTICS INC stock?
SNSE has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the GICS sector and industry of SNSE stock?
SENSEI BIOTHERAPEUTICS INC (SNSE) operates in the Health Care sector and the Biotechnology industry.
Can you provide the PE ratio for SNSE stock?
SENSEI BIOTHERAPEUTICS INC (SNSE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-19.13).
Can you provide the upcoming earnings date for SENSEI BIOTHERAPEUTICS INC?
SENSEI BIOTHERAPEUTICS INC (SNSE) will report earnings on 2026-03-26, after the market close.
SNSE Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to SNSE. When comparing the yearly performance of all stocks, SNSE turns out to be only a medium performer in the overall market: it outperformed 57.13% of all stocks.
SNSE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SNSE. While SNSE has a great health rating, there are worries on its profitability.
SNSE Financial Highlights
Over the last trailing twelve months SNSE reported a non-GAAP Earnings per Share(EPS) of -19.13. The EPS increased by 19.62% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -87.5% | ||
| ROE | -104.92% | ||
| Debt/Equity | 0 |
SNSE Forecast & Estimates
8 analysts have analysed SNSE and the average price target is 33.15 USD. This implies a price increase of 185.41% is expected in the next year compared to the current price of 11.615.